Predictive Models

There are a number of models that allow doctors to assist patients in predicting the risk of prostate cancer recurrence following therapy. These nomograms (mathematical models) are used to predict the risk of PSA failure after treatment and may help to educate men and their families to the risk of suffering PSA failure after surgery or radiation therapy. PSA failure refers to a rising PSA after treatment.

It should be remembered that these models have accuracy rates somewhere in the 75% range. While these models are useful during discussions about treatments of prostate cancer, models should be placed into perspective by the patient and physician with regard to the individual patient’s overall health status and personal preferences for treatment.

Discussing cancer treatment options are perplexing. Patient’s anxieties can be relieved by understanding the high chances of overall success from either radiation therapy or surgical treatment options. Urologists and radiation treatment specialists have been early pioneers in the use of mathematical models for educating patients. Any questions that patients may have about the use of these models should be brought up during their discussion with their doctors.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Movember Foundation 2018

Movember 2018

The Movember Foundation's fundraiser runs from November 1 to 30.  Click here to donate to The Vancouver Prostate Centre team as we join teams across Canada to raise funds for men's health research in the areas of prostate cancer, testicular cancer, mental health and suicide prevention.

Employment

Work at the Vancouver Prostate Centre

Tuesday, November 27, 2018

An innovative new study advances personalized medicine for prostate cancer patients

Drs Chi and Wyatt
Tuesday, October 23, 2018

Three researchers receive Prostate Cancer Canada & Movember Foundation grants for biomarker development